Table 3.

Crude MDS/AML rates by treatment category

Treatment category	% (cases/no. in category) (95% CI)
2 years of follow up (n = 5790)
All patients	.29 (17/5790) (.17, .47)
Surgery only	0 (0/420) (0)
Surgery/radiation	.25 (7/2764) (.10, .52)
Surgery/chemotherapy	.16 (1/639) (.00, .87)
Surgery/radiation/chemotherapy	.41 (9/1959) (.21, .87)
Anthracycline regimen	.25 (5/1968) (.08, .59)
Non-anthracycline regimen	.47 (3/633) (.10, 1.38)
5 years of follow up (n = 4179)
All patients	.41 (17/4179) (.24, .65)
Surgery only	0 (0/222) (0)
Surgery/radiation	.24 (5/2058) (.08, .57)
Surgery/chemotherapy	.22 (1/461) (.01, 1.20)
Surgery/radiation/chemotherapy	.42 (6/1440) (.15, .90)
Anthracycline regimen	.15 (2/1368) (.02, .53)
Non-anthracycline regimen	.56 (3/531) (.12, 1.64)